These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7984290)

  • 1. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zatosetron. (LY 191617, LY 277359).
    Drugs R D; 1999 Dec; 2(6):397-9. PubMed ID: 10763451
    [No Abstract]   [Full Text] [Related]  

  • 4. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.
    Smith WT; Londborg PD; Blomgren SL; Tollefson GD; Sayler ME
    J Clin Psychopharmacol; 1999 Apr; 19(2):125-31. PubMed ID: 10211913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
    Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A
    Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
    Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E
    Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
    Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ
    J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on migraine headache of MDL 72,222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study.
    Loisy C; Beorchia S; Centonze V; Fozard JR; Schechter PJ; Tell GP
    Cephalalgia; 1985 Jun; 5(2):79-82. PubMed ID: 3893732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
    Robertson DW; Lacefield WB; Bloomquist W; Pfeifer W; Simon RL; Cohen ML
    J Med Chem; 1992 Jan; 35(2):310-9. PubMed ID: 1732548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic toxicity, metabolism, and pharmacokinetics of the 5-HT3 receptor antagonist zatosetron (LY277359) in Fischer 344 rats.
    Bendele AM; Buenger DA; McGrath JP; Schmalz CA; Hanasono GK
    Fundam Appl Toxicol; 1994 May; 22(4):494-504. PubMed ID: 8056197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 15. First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
    Couturier EG; Hering R; Foster CA; Steiner TJ; Clifford Rose F
    Headache; 1991 May; 31(5):296-7. PubMed ID: 1650335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons.
    Rasmussen K; Stockton ME; Czachura JF
    Eur J Pharmacol; 1991 Nov; 205(1):113-6. PubMed ID: 1811993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers.
    Grande L; Lacima G; Pérez A; Zayas JM
    Br J Clin Pharmacol; 1995 Oct; 40(4):401-3. PubMed ID: 8554943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.
    Ring BJ; Parli CJ; George MC; Wrighton SA
    Drug Metab Dispos; 1994; 22(3):352-7. PubMed ID: 8070310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1990 Jul; 254(1):350-5. PubMed ID: 2366187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.